Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 5 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line Ibrutinib (Imbruvica) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib in combination with venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma – first line Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma Lisocabtagene maraleucel (Liso-cel; JCAR017) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications